THE MCMANUS GROUP for AMGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5378: Lower Costs More Transparency Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, and S.1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act, H.R. 7623 - Telehealth Modernization Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAWREN D GEER | — |
| JOHN MCMANUS | — |
| ALEX WHALEN | — |
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to commercial delinking of PBMs in H.R. 6283/S.1542
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAWREN D GEER | — |
| JOHN MCMANUS | — |
| ALEX WHALEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.